Linked Life Data

10592433

Source:http://linkedlifedata.com/resource/pubmed/id/10592433

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-1-13
pubmed:abstractText
Cell proliferation in uterine leiomyomas treated preoperatively with either nafarelin (400 microg/day) for 3 months (7 patients) or nafarelin plus hormone (oestradiol + norethisterone) add-back therapy (6 patients) was investigated by automatic image analysis of frozen tissue sections using immunohistochemistry with anti-proliferating cell nuclear antigen antibody. GnRHa therapy decreased cell proliferation in leiomyomas to a level corresponding to the situation previously seen in postmenopausal leiomyomas. However, there was no consistent correlation between cell proliferation and shrinkage of leiomyomal size. The hormone add-back therapy moderated the influence of GnRHa on cell proliferation and completely blocked a decrease in size of leiomyomas in our patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0378-7346
pubmed:author
pubmed:copyrightInfo
Copyright 1999 S. Karger AG, Basel
pubmed:issnType
Print
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
276-9
pubmed:dateRevised
2009-12-16
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
GnRH analogues and uterine leiomyomas. Effect of hormone replacement therapy on cell proliferation.
pubmed:affiliation
Department of Anaesthesiology and Intensive Care, Tampere University Hospital, Tampere, Finland.
pubmed:publicationType
Journal Article, Clinical Trial